ClinicalTrials.gg
WithdrawnNCT07313800EMBRACEUpdated Oct 27, 2026

EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization

An interventional study of TEMMA Endovascular Treatment in Migraine Disorders, Refractory Migraine and Chronic Migraine, sponsored by Cortex Neurovascular. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Cortex Neurovascular · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
The study was not initiated. IRB review determined the study would require an investigational device exemption (IDE), and the sponsor elected not to proceed because resources were not available. No subjects were enrolled.
Updated Oct 27, 2026Now WithdrawnEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
591st of 610
0 · median 78
Started
2028
the only one that year
No phase
204 of 697
31 open now
Registered
663rd of 697
by date

Among the 697 studies in Migraine Disorders with a site in United States, this one is the 591st largest by enrollment of the 610 interventional ones that give a count, is the only one that started in 2028, is one of 204 with no phase, and was the 663rd registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 92 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 697 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).

Read the detailed description

This is an investigator-initiated, prospective, single-site, open-label pilot study designed to evaluate the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment approach targeting meningeal arterial contributors to migraine symptoms. TEMMA represents a structured clinical program applying endovascular treatment principles to patients with refractory migraine.

Participants undergo a baseline assessment period that includes prospective headache diary collection, capturing headache presence, pain intensity, and acute medication use, along with baseline migraine-related disability and quality-of-life assessments. Endovascular treatment is performed as part of the TEMMA program using FDA-cleared devices in accordance with institutional clinical practice. Procedural techniques, vessel selection, materials, adjunctive assessments, and treatment sequencing are determined by the treating physician and are not fully standardized within this pilot study.

Adjunctive assessments, which may include intra-procedural physiologic or pharmacologic evaluations, may be performed at the discretion of the treating physician to inform clinical decision-making but are not required for study participation and are not used as mandatory eligibility criteria.

Participants are followed longitudinally with serial headache diary data and standardized patient-reported outcome measures collected at predefined intervals through 12 months following treatment. The primary endpoint is change in monthly headache days compared with baseline. Secondary endpoints include changes in headache intensity, acute medication use, migraine-related disability, quality of life, and durability of symptom improvement.

Safety is monitored throughout the study through adverse event reporting with independent physician oversight.

03

Conditions studied

  • Migraine Disorders
  • Refractory Migraine
  • Chronic Migraine

Browse trials for

Keywords

  • Middle Meningeal Artery Embolization
  • MMA Embolization
  • Refractory Migraine
  • Coil Embolization
  • Neurovascular Intervention
  • Migraine Prevention
  • TEMMA
  • TEMMA procedure
  • TEMMA protocol
  • Targeted Embolization for Migraine Management
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-60 years
  • Diagnosis of migraine (with or without aura)

    -≥8 headache days per month

  • Failure of ≥2 preventive medication classes
  • Ability to complete electronic headache diary and surveys
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Secondary headache disorders
  • Prior MMA embolization
  • to angiography or embolization
  • Pregnancy
  • Inability to comply with follow-up
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TEMMA Procedure (Targeted Embolization for Migraine Management)

    Participants with refractory migraine undergo the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy addressing meningeal arterial contributors to migraine. Treatment is performed using FDA-cleared devices per institutional clinical practice. Procedural details and adjunctive assessments are individualized and not dictated by the study protocol. Outcomes are evaluated using within-subject comparison to baseline.

    Device: TEMMA Endovascular Treatment

Interventions

  • DeviceTEMMA Endovascular Treatment

    Endovascular treatment targeting meningeal arterial contributors to migraine performed as part of the TEMMA procedure (Targeted Embolization for Migraine Management) using FDA-cleared devices. Procedural techniques and adjunctive assessments are individualized at the discretion of the treating physician and are not standardized within the study.

06

What researchers measure

Primary outcomes

  1. Change in Monthly Headache Days Post-Embolization

    Change from baseline in the number of headache days per month following bilateral middle meningeal artery coil embolization, assessed via SMS-based headache diary.

    Time frame: Baseline to 12 months post-embolization

Secondary outcomes

  1. Change in Headache Intensity

    Change from baseline in average headache pain intensity (0-10 scale), assessed via SMS-based headache diary.

    Time frame: Baseline to 12 months post-embolization

  2. Change in Acute Medication Use

    Change from baseline in the number of days with acute migraine medication use per month.

    Time frame: Baseline to 12 months post-embolization.

  3. Change in Migraine Disability Assessment (MIDAS) Score

    Change from baseline in MIDAS score, a validated measure of migraine-related disability.

    Time frame: Baseline to 3 months (assessed at 1, 3, 6, and 12 months).

  4. Change in Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Score

    Change from baseline in MSQ v2.1 score, a validated measure of migraine-specific quality of life.

    Time frame: Baseline to 3 months (assessed at 1, 3, 6, and 12 months).

  5. Time to Symptom Recurrence Following Lidocaine Testing

    Duration of symptom improvement (time to return to baseline headache frequency/intensity) after bilateral MMA lidocaine testing.

    Time frame: Up to 4 weeks post-lidocaine testing.

  6. Time to Symptom Recurrence Following Embolization

    Duration of symptom improvement (time to return to baseline headache frequency/intensity) after bilateral MMA coil embolization.

    Time frame: Up to 12 months post-embolization.

07

Study locations

1 site
  • Cortex Neurovascular / TRA Union
    Tacoma, Washington 98405, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Mar 2028; primary completion for Mar 2030, 24 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Mar 2026 → Mar 2028, primary completion Mar 2027 → Mar 2030 and completion Mar 2028 → Mar 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 2, 2026
StartEst.
Mar 1, 2028was Mar 2026
Primary completionEst.
Mar 1, 2030was Mar 2027
CompletionEst.
Mar 1, 2032was Mar 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn The study was not initiated. IRB review determined the study would require an investigational device exemption (IDE), and the sponsor elected not to proceed because resources were not available. No subjects were enrolled.
changed Oct 27, 2026
Start date
Mar 1, 2026→Mar 1, 2028
Oct 20, 2026
Primary completion
Mar 1, 2027→Mar 1, 2030
Oct 20, 2026
Study completion
Mar 1, 2028→Mar 1, 2032
Oct 20, 2026
Enrollment
25 (estimated)→0 (actual)
Oct 27, 2026
Show all 2 updates
  1. Oct 27, 2026
    Not yet recruiting→Withdrawn
    Why stopped The study was not initiated. IRB review determined the study would require an investigational device exemption (IDE), and the sponsor elected not to proceed because resources were not available. No subjects were enrolled.
    Enrollment 25 (estimated)→0 (actual)
    + 1 other change: contact details
  2. Oct 20, 2026
    Start date Mar 1, 2026→Mar 1, 2028
    Primary completion Mar 1, 2027→Mar 1, 2030
    Study completion Mar 1, 2028→Mar 1, 2032
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07313800
Lead sponsor
Cortex Neurovascular
Responsible party
Sponsor
First posted
Jan 2, 2026
Start date
Mar 1, 2028 (estimated)
Primary completion
Mar 1, 2030 (estimated)
Completion
Mar 1, 2032 (estimated)
Last update
Oct 27, 2026

Study contacts

Dennis Wang, MD
principal investigator · Cortex Neurovascular

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion